Clinical Trial Update: Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial of GTAEXS617 in adults with advanced solid tumors is currently recruiting. The study encompasses head and neck squamous cell carcinom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Head and Neck Squamous Cell Carcinoma
• High-grade Serous Ovarian Cancer
• Hr-positive Breast Cancer
• Non-small Cell Lung Cancer
• Pancreatic Adenocarcinoma
• Peritoneal Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• GTAEXS617 (GTAEXS617)

Snippet

Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma | Phase 1, Phase 2 | Status: RECRUITING